KalVista Pharmaceuticals (KALV) Profit After Tax (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Profit After Tax of -$60.1 million in Q3 2025, down 15.07% quarter-over-quarter from -$52.2 million in Q2 2025, and down 48.59% year-over-year from -$116.9 million in Q3 2024.
KalVista Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$60.1 million for Q3 2025.
- In Q3 2025, Profit After Tax fell 48.59% year-over-year to -$60.1 million; the TTM figure through Jul 2025 stood at -$195.0 million (down 37.57% YoY), while the FY2025 annual figure was -$183.4 million, down 44.85% from the prior year.
- Profit After Tax came in at -$60.1 million for Q3 2025 at KalVista Pharmaceuticals, down from -$52.2 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$10.0 million in Q1 2021 to a low of -$60.1 million in Q3 2025.
- A 5-year average of -$29.0 million and a median of -$24.7 million in 2022 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax sank 127.12% in 2021 and gained 5.18% in 2023, its largest moves.
- KalVista Pharmaceuticals' Profit After Tax stood at -$19.6 million in 2021, then declined by 13.27% to -$22.3 million in 2022, then dropped by 24.23% to -$27.6 million in 2023, then plunged by 52.87% to -$42.3 million in 2024, then sank by 42.18% to -$60.1 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$60.1 million, -$52.2 million, and -$42.3 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -60.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -60.10 Mn |
| Apr 30, 2025 | -52.23 Mn |
| Oct 31, 2024 | -42.27 Mn |
| Jul 31, 2024 | -40.44 Mn |
| Apr 30, 2024 | -44.65 Mn |
| Jan 31, 2024 | -29.03 Mn |
| Oct 31, 2023 | -27.65 Mn |
| Jul 31, 2023 | -25.32 Mn |
| Apr 30, 2023 | -26.31 Mn |
| Jan 31, 2023 | -21.30 Mn |
| Oct 31, 2022 | -22.26 Mn |
| Jul 31, 2022 | -23.04 Mn |
| Apr 30, 2022 | -24.11 Mn |
| Jan 31, 2022 | -22.47 Mn |
| Oct 31, 2021 | -19.65 Mn |
| Jul 31, 2021 | -16.11 Mn |
| Apr 30, 2021 | -14.96 Mn |
| Jan 31, 2021 | -10.05 Mn |
| Oct 31, 2020 | -10.43 Mn |
| Jul 31, 2020 | -10.81 Mn |
| Apr 30, 2020 | -6.59 Mn |
| Jan 31, 2020 | -9.29 Mn |
| Oct 31, 2019 | -5.90 Mn |
| Jul 31, 2019 | -7.34 Mn |
| Apr 30, 2019 | -8.53 Mn |
| Jan 31, 2019 | -3.96 Mn |
| Oct 31, 2018 | -3.30 Mn |
| Jul 31, 2018 | -5.03 Mn |
| Apr 30, 2018 | -657,000.00 |
| Jan 31, 2018 | -5.23 Mn |
| Oct 31, 2017 | -4.99 Mn |
| Jul 31, 2017 | -4.93 Mn |
| Apr 30, 2017 | -4.20 Mn |
| Jan 31, 2017 | -7.64 Mn |
| Oct 31, 2016 | -3.30 Mn |
| Jul 31, 2016 | -3.44 Mn |
| Mar 31, 2016 | -6.61 Mn |
| Dec 31, 2015 | -5.66 Mn |
| Sep 30, 2015 | -4.99 Mn |
| Jun 30, 2015 | -9.01 Mn |
| Mar 31, 2015 | -5.18 Mn |
| Dec 31, 2014 | -4.71 Mn |
| Sep 30, 2014 | -4.00 Mn |
| Jun 30, 2014 | -2.64 Mn |
| Mar 31, 2014 | -2.02 Mn |